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controls. A significant difference in the total number of
variants in ALS-associated genes was not observed.
Further, PCA clustering analysis did not suggest an
observable difference in genetic variance between
C9orf72-positive patients and unknown cause patients,
nor between ethnicity, gender, or site of disease onset
groups.
Discussion: The oligogenic hypothesis could help to
explain why certain genes have been statistically associated
with ALS, but that single mutations are often not
sufficient to cause the disease in all mutation carriers.
However, because we did not observe a significantly
increased burden of mutations within the ALS genes, it is
unlikely that the disease is caused by carrying multiple
mutations in these genes at once. It may be that there
remain several genes yet to be associated with ALS that
will explain the disease in these unknown-cause patients.
Conclusion: Our evidence does not support the oligo-
genic hypothesis in ALS.
DOI: 10.1080/21678421.2017.1371515/0030
GEN-31 Genetic testing of sporadic
ALS patients reveals pathogenetic
mutations in non-ALS genes
M Valente1, S Zucca1, I Palmieri1, J Garau1,
F Rey1,2, S Gagliardi1, L Diamanti3,4,
M Ceroni3,4, C Cereda1
1Genomic and Post-Genomic Center, ‘‘C.
Mondino’’ National Neurological Institute,
Pavia, Italy, 2Department of Biology and
Biotechnology, University of Pavia, Pavia, Italy,
3Department of Brain and Behavioral Science,
University of Pavia, Pavia, Italy, 4Unit of General
Neurology, ‘‘C. Mondino’’ National Neurological
Institute, Pavia, Italy
Email address for correspondence:
marialuisa.valente@mondino.it
Keywords: ALS, next-generation sequencing, neurodegenera-
tive panel
Background: The rise of next-generation sequencing
(NGS), allowing fast and cheap massive-parallel DNA
sequencing, in genetic testing has revolutionized the
approach to diagnosis in neurodegenerative diseases.
The traditional approach, which considered different
neurodegenerative diseases as separated conditions,
mainly associated to groups of known canonical genes,
has been overturned by the advent of multiple genes and
exomes panels. Increasing evidence supports the existence
of a close relationship between genetic profiles of different
neurodegenerative diseases, further reinforcing the
hypothesis of a co-morbidity between these disorders.
Materials and methods: In this study, DNA extracted
from blood of 63 sporadic ALS patients has been
sequenced with a newly-defined customized
‘neurodegenerative panel’ (SureSelect, Agilent), contain-
ing classical ALS genes such as SOD1, TARDBP and FUS,
together with Parkinsonian genes such as PINK1 and
LRRK2, and genes involved in different neuropathies (eg
Charcot-Marie-Tooth, Hereditary spastic paraplegia), for
a total of 103 genes. DNA-seq was performed using an
Illumina MiSeq sequencer and data analysis was per-
formed according to the best practices described for these
applications to identify single nucleotide variants and
small insertions/deletions. Pathogenic and likely patho-
genic mutations have been confirmed via Sanger
sequencing.
Results: For six patients, mutations in classical ALS
genes have been identified. Three patients have mutations
in the SOD1 gene, Two with p.G147S and one p.G93D,
one in FUS gene p.G302A and two brothers with
mutation in VCP gene (p.R191Q). Surprisingly, likely
pathogenetic mutations in non-canonical ALS genes such
as PINK1, LRRK2, BAG3 and PDYN were also found.
These genes have not been reported to be associated to
ALS, but associated to Parkinson’s disease and
Spinocerebellar Ataxia 23. Two ALS cases have a very
rare nucleotide substitution in LRRK2: rs141252946 and
p.E1011D, and one presents a mutation in BAG3 gene
p.R71W and one in PDYN E192V.
Conclusion: These findings support the hypothesis of the
existence of a comorbidity between neurodegenerative
diseases and strongly highlight the importance of wide
genetic screenings on genes not yet associated to the
studied disease. It is clear that the old genotype-phenotype
view is quite simplistic and the approach to the disease
must be changed.
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Background: Understanding genetic modifiers of motor
neuron disease can provide insight into the mechanisms
underlying these disorders. Increasing evidence suggests
that common pathways are perturbed across motor
neuron diseases and therefore identified genetic modifiers
could have an effect across multiple diseases. Plastin 3
(PLS3) is a known genetic modifier of spinal muscular
atrophy (SMA) and while implicated as a possible cross-
disease modifier, it has yet to be tested.
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